Arthex Biotech to raise a €4.25 million funding round

Arthex Biotech, a Valencia, Spain-based biotech company, announced adding more capital investment in a new € 4.25 million funding round.

This round completes an initial round of seed capital of 2.7 million from Invivo Ventures in December 2019 and CDTI, through its Innvierte program, in June 2020. In total, the funds raised by ARTHEx amount to 6.95 million euros.

In conjunction with the financing, Alain Huriez, chairman and managing partner at AFB, will join Arthex’s board of directors, alongside the managing partners of Invivo Ventures, Luis Pareras and Albert Ferrer.

With the new investment made by Advent France Biotechnology (AFB) and Invivo Ventures, ARTHEx aims to make its therapy available for the first human clinical trial in 2022, once it completes the optimization of the drug candidate that is currently underway and the successive necessary preclinical regulatory studies.

ARTHEx was founded in September 2019. Researchers Dr. Rubén Artero and Dra. Beatriz Llamusí for a promising RNA therapy developed by the translational genomics research group of the Universitat de València (UV) and the INCLIVA Health Research Institute could reach DM1 patients. The proof of concept carried out on an animal model of the disease was published in the prestigious journal Nature Communications . This therapy is protected by a patent application owned by the UV and licensed to ARTHEx.